According to Olin Biology, the National Medical Products Administration website recently announced that it has agreed to accept the application for clinical trials of Olin Biology's trivalent influenza virus split vaccine (MDCK cells), which is also the first domestically declared clinical cellular substrate trivalent influenza vaccine.
欧林生物：三价流感病毒裂解疫苗（MDCK细胞）临床试验申请获得受理
Olin Biology: The clinical trial application for trivalent influenza virus split vaccine (MDCK cells) has been accepted.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.